Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Dragonfly Therapeutics
Tizona Therapeutics, Inc
Novartis
Inhibrx Biosciences, Inc
MacroGenics
DEKA Biosciences
Rapa Therapeutics LLC
Inhibrx Biosciences, Inc
Second Affiliated Hospital of Guangzhou Medical University
iTeos Therapeutics
Presage Biosciences
Celldex Therapeutics
GeneMedicine Co., Ltd.
University Hospital, Ghent
Kineta Inc.
Seagen Inc.
Fate Therapeutics
Rakuten Medical, Inc.
Incyte Corporation
Incyte Corporation
Dynavax Technologies Corporation
Oncovir, Inc.
Lytix Biopharma AS